» Articles » PMID: 31256702

Hidden Burden of Electronic Health Record-Identified Familial Hypercholesterolemia: Clinical Outcomes and Cost of Medical Care

Abstract

Background Familial hypercholesterolemia ( FH ), is a historically underdiagnosed, undertreated, high-risk condition that is associated with a high burden of cardiovascular morbidity and mortality. In this study, we use a population-based approach using electronic health record ( EHR )-based algorithms to identify FH . We report the major adverse cardiovascular events, mortality, and cost of medical care associated with this diagnosis. Methods and Results In our 1.18 million EHR- eligible cohort, International Classification of Diseases, Ninth Revision ( ICD -9) code-defined hyperlipidemia was categorized into FH and non- FH groups using an EHR algorithm designed using the modified Dutch Lipid Clinic Network criteria. Major adverse cardiovascular events, mortality, and cost of medical care were analyzed. A priori associated variables/confounders were used for multivariate analyses using binary logistic regression and linear regression with propensity score-based weighted methods as appropriate. EHR FH was identified in 32 613 individuals, which was 2.7% of the 1.18 million EHR cohort and 13.7% of 237 903 patients with hyperlipidemia. FH had higher rates of myocardial infarction (14.77% versus 8.33%; P<0.0001), heart failure (11.82% versus 10.50%; P<0.0001), and, after adjusting for traditional risk factors, significantly correlated to a composite major adverse cardiovascular events variable (odds ratio, 4.02; 95% CI, 3.88-4.16; P<0.0001), mortality (odds ratio, 1.20; CI, 1.15-1.26; P<0.0001), and higher total revenue per-year (incidence rate ratio, 1.30; 95% CI, 1.28-1.33; P<0.0001). Conclusions EHR -based algorithms discovered a disproportionately high prevalence of FH in our medical cohort, which was associated with worse outcomes and higher costs of medical care. This data-driven approach allows for a more precise method to identify traditionally high-risk groups within large populations allowing for targeted prevention and therapeutic strategies.

Citing Articles

Current US prevalence of myocardial injury patterns and clinical outcomes among hospitalised patients with familial hypercholesterolaemia: insight from the National Inpatient Sample-a retrospective cohort study.

Kumi D, Narh J, Odoi S, Oduro A, Gajjar R, Gwira-Tamattey E BMJ Open. 2024; 14(5):e077839.

PMID: 38806434 PMC: 11138297. DOI: 10.1136/bmjopen-2023-077839.


Measuring Costs of Cardiovascular Disease Prevention for Patients with Familial Hypercholesterolemia in Administrative Claims Data.

Passero L, Roberts M High Blood Press Cardiovasc Prev. 2024; 31(2):215-219.

PMID: 38308804 DOI: 10.1007/s40292-024-00624-6.


Cost-Effectiveness of Screening Strategies for Familial Hypercholesterolaemia: An Updated Systematic Review.

Marquina C, Morton J, Lloyd M, Abushanab D, Baek Y, Abebe T Pharmacoeconomics. 2024; 42(4):373-392.

PMID: 38265575 PMC: 10937756. DOI: 10.1007/s40273-023-01347-7.


The burden of severe hypercholesterolemia and familial hypercholesterolemia in a population-based setting in the US.

Saadatagah S, Alhalabi L, Farwati M, Zordok M, Bhat A, Smith C Am J Prev Cardiol. 2022; 12:100393.

PMID: 36204653 PMC: 9530843. DOI: 10.1016/j.ajpc.2022.100393.


Harnessing Electronic Medical Records in Cardiovascular Clinical Practice and Research.

Gouda P, Ezekowitz J J Cardiovasc Transl Res. 2022; 16(3):546-556.

PMID: 36103036 DOI: 10.1007/s12265-022-10313-1.


References
1.
Patel P, Hu Y, Kolinovsky A, Geng Z, Ruhl J, Krishnamurthy S . Hidden Burden of Electronic Health Record-Identified Familial Hypercholesterolemia: Clinical Outcomes and Cost of Medical Care. J Am Heart Assoc. 2019; 8(13):e011822. PMC: 6662375. DOI: 10.1161/JAHA.118.011822. View

2.
Perak A, Ning H, de Ferranti S, Gooding H, Wilkins J, Lloyd-Jones D . Long-Term Risk of Atherosclerotic Cardiovascular Disease in US Adults With the Familial Hypercholesterolemia Phenotype. Circulation. 2016; 134(1):9-19. PMC: 4933328. DOI: 10.1161/CIRCULATIONAHA.116.022335. View

3.
Abul-Husn N, Manickam K, Jones L, Wright E, Hartzel D, Gonzaga-Jauregui C . Genetic identification of familial hypercholesterolemia within a single U.S. health care system. Science. 2016; 354(6319). DOI: 10.1126/science.aaf7000. View

4.
Marang-van de Mheen P, Ten Asbroek A, Bonneux L, Bonsel G, Klazinga N . Cost-effectiveness of a family and DNA based screening programme on familial hypercholesterolaemia in The Netherlands. Eur Heart J. 2002; 23(24):1922-30. DOI: 10.1053/euhj.2002.3281. View

5.
Gandra S, Villa G, Fonarow G, Lothgren M, Lindgren P, Somaratne R . Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States. Clin Cardiol. 2016; 39(6):313-20. PMC: 5074319. DOI: 10.1002/clc.22535. View